Comments
Cadila Healthcare Ltd (Zydus Cadila) has posted a standalone net profit of Rs 306 crore for the quarter ended December 2017 up from Rs 22 crore reported in the corresponding quarter a year ago.
Total revenues of the company for the period stood at Rs 1,632 crore against Rs 825 crore in the same quarter last year.
For the nine-month period, the company's net profit stood at Rs 848 crore against Rs 190 crore reported in the same period a year ago. Total revenues for the nine-month period stood at Rs 4,545 crore, up from Rs 2,624 crore in the same quarter last year.
On a consolidated basis, the net profit stood at Rs 543 crore during the third quarter against Rs 324 crore in the same quarter last year. Total consolidated income for the quarter stood at Rs 3,301 crore against Rs 2,380 crore reported last year.
Consolidated profit for the nine-month period stood at Rs 1,185 crore, up from Rs 1,102 crore in the same period last year. Total consolidated income for the period stood reported at Rs 8,807 crore, up from Rs 7,156 crore in the corresponding quarter a year ago.
"During the quarter, the company received approval for 24 new products for the US market and filed 10 additional ANDAs with the USFDA. The company launched 2 new products in the US during the quarter. In India, the company launched 12 new products, including line extensions," a company statement said here.
Cadila Healthcare shares were trading higher by 4.05 per cent at Rs 412.35 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.